Filter
Period
Filter by
recent search
Showing: 1 – 05 of 123 Regulated Information
–
07 January 2025
07 January 2025
Ipsen – December 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
09 December 2024
09 December 2024
Ipsen – November 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
07 November 2024
07 November 2024
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
09 October 2024
09 October 2024
–
18 September 2024
18 September 2024
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
PARIS, FRANCE, 16 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today final data from the CABINET Phase III trial investigating Cabometyx® (cabozantinib) versus placebo in people living with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors…